Dr. Wee on androgen receptor inhibitors for the management of nonmetastatic CRPCOctober 3rd 2022
Christopher Wee, MD, discusses available androgen receptor inhibitors and unmet needs regarding the optimal use of these agents for patients with nonmetastatic castration-resistant prostate cancer.
Neoadjuvant combo boosts MRD negativity rates in high-risk prostate cancerSeptember 28th 2022
Adding apalutamide to the hormone therapy degarelix in the neoadjuvant setting increased the likelihood of achieving minimal residual disease negativity in patients with high-risk prostate cancer after radical prostatectomy.
Dr. Linehan on her experience and learning curve with HIFUSeptember 28th 2022
“I feel like [HIFU] provided patients this intermediary treatment option…It was less invasive than radiation and surgery, but still provided cancer control, or at least for some patients delayed the time until they needed a more radical treatment,” says Jennifer A. Linehan, MD.
Consider financial toxicity when recommending novel hormonal therapies for prostate cancerSeptember 27th 2022
"Ultimately, it will be the treating physician’s responsibility to identify cost-effective alternatives and available resources to help mitigate the financial toxicity incurred from novel cancer therapies," writes Badar M. Mian, MD.
Pushing past the pandemic’s impact on prostate cancer screeningSeptember 26th 2022
"Cancer doesn’t take a holiday or vacation, and it doesn’t care about a pandemic. Our efforts to reduce deaths from prostate cancer through screening and early detection must continue," writes Michael S. Cookson, MD, MMHC.
Investigators evaluate out-of-pocket costs for advanced prostate cancer treatmentsSeptember 23rd 2022
“We found that treatment-related out-of-pocket costs were 18 times higher for those patients treated with novel hormonal therapies compared to those who were just on standard ADT,” says Daniel D. Joyce, MD.
Cholesterol-lowering drug tested for effect on prostate cancer tumorsAugust 31st 2022
“We have a much larger minority population, and so the ability for us to identify how this type of intervention may impact a variety of minority or underserved populations is interesting,” said Stephen Savage, MD, vice chairman of the Department of Urology.
Clinic helps patients prepare to move beyond prostate cancerAugust 16th 2022
“The benefit of the clinic is a holistic approach to the survivorship care that takes into account things that we as urologists don’t usually consider in our everyday patient encounters,” said Niels Johnsen, MD, MPH, assistant professor of Urology, Division of Reconstructive Urology and Pelvic Health, Vanderbilt University Medical Center.
FDA grants priority review to olaparib/abiraterone combo for mCRPCAugust 16th 2022
The application is supported by the phase 3 PROpel trial, which showed that adding olaparib to frontline abiraterone acetate and prednisone/prednisolone significantly improved radiographic progression-free survival in patients with mCRPC.
Do 5-ARIs protect against death from prostate cancer?August 12th 2022
"It is evident...that the safety of 5-ARIs as it relates to prostate cancer outcomes is contingent upon the clinician understanding its effect on PSA level and making appropriate adjustments to ensure timely deployment of diagnostic imaging and biopsy," writes Badar M. Mian, MD.
The effects of exercise before and after a prostate cancer diagnosisAugust 11th 2022
"This article serves as a summary of the literature published in the past 3 years, documenting the impact of exercise and physical activity on prostate cancer development and on cancer-specific, treatment-related, and patient-reported outcomes," writes Christine Ibilibor, MD, MSc.